-
Egalet Gets Grilled On Earnings Call By Unverified Caller
Monday, March 13, 2017 - 12:26pm | 474Read More...Egalet Corp (NASDAQ: EGLT), the specialty pharmaceutical company that develops and commercializes treatments for pain and other conditions, likely got "trolled" during its conference call. During the conference call's Q&A session, an analyst named Christina Hung from Goldman Sachs...
-
Egalet Reports Q3 Results, Offers ARYMO ER Updates
Friday, November 4, 2016 - 7:24am | 118Read More...Egalet Corp (NASDAQ: EGLT) lost $1.10 per share in its third quarter and missed estimates by $0.20 per share. Revenue of $4.7 million beat by $0.1 million. Company highlighted FDA Advisory Committee's recommended approval of ARYMO ER during the quarter. Company also highlighted...
-
Why Egalet's FDA PDUFA Delay Is No Cause For Panic
Monday, October 17, 2016 - 1:20pm | 370Read More...Shares of Egalet Corp (NASDAQ: EGLT) traded lower by more than 5 percent Monday morning after a scheduled meeting with the U.S. Food and Drug Administration (FDA) to discuss its delayed ARYMO ER therapy. Egalet said in a press release that the FDA "has identified no particular issue with our...
